title: [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
abstract: A 25-year-old man with RS rectal cancer received a radical resection of the original tumor and lymph node dissection. Oral tegafur/uracil (UFT)/Leucovorin (LV) therapy has been used for adjuvant chemotherapy, as the pathological Stage was T3N1M0, Stage IIIa. After 10 months from operation, multiple liver metastases were recognized and not resectable. So a systemic chemotherapy by mFOLFOX6+bevacizumab was begun via CV port. After 5 courses of mFOLFOX6+bevacizumab, abdominal CT revealed liver metastases showed remarkable reduction in size. Hepatic resection of S6 segment was enforced, and the patient uneventfully discharged. Pathological findings of S6 segment revealed no residual cancer cells, indicating the histological effect of mFOLFOX6+bevacizumab was Grade 3. And no liver damage was recognized.
authors.affiliation: Department of Surgery, National Hospital Organization Fukuyama Medical Center.
authors.forename: Shinya
authors.initials: S
authors.lastname: Otsuka
authors.forename: Masaru
authors.initials: M
authors.lastname: Inagaki
authors.forename: Manabu
authors.initials: M
authors.lastname: Nishie
authors.forename: Ryousuke
authors.initials: R
authors.lastname: Hamano
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Tokunaga
authors.forename: Kenji
authors.initials: K
authors.lastname: Takahashi
authors.forename: Yousuke
authors.initials: Y
authors.lastname: Tsunemitsu
authors.forename: Kazuya
authors.initials: K
authors.lastname: Miyoshi
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Iwakawa
authors.forename: Masahiko
authors.initials: M
authors.lastname: Takahashi
authors.forename: Hiromi
authors.initials: H
authors.lastname: Iwagak
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000473:pathology* / Q000601:surgery; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008297:Male; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000556:secondary*; D009944:Organoplatinum Compounds / Q000008:administration & dosage
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil